Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial von Cramer, Paula, Tresckow, Julia V, Robrecht, Sandra, Bahlo, Jasmin, Fürstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J, Vehling-Kaiser, Ursula, Dürig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the... von Goergen, Ellinor, Tresckow, Julia v., Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Al-Sawaf, Othman, Fürstenau, Moritz, Simon, Florian, Kutsch, Nadine, Nieper, Pascal, Tausch, Eugen, Ritgen, Matthias, Böttcher, Sebastian, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Langerbeins, Petra, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula

Volltext

CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials... von Goergen, Ellinor, Tresckow, Julia v., Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Al-Sawaf, Othman, Fürstenau, Moritz, Simon, Florian, Kutsch, Nadine, Nieper, Pascal, Tausch, Eugen, Ritgen, Matthias, Böttcher, Sebastian, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Langerbeins, Petra, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula

Volltext

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial von Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Volltext

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial von Borchmann, Peter, Plütschow, Annette, Kobe, Carsten, Greil, Richard, Meissner, Julia, Topp, Max S, Ostermann, Helmut, Dierlamm, Judith, Mohm, Johannes, Thiemer, Julia, Sökler, Martin, Kerkhoff, Andrea, Ahlborn, Miriam, Halbsguth, Teresa V, Martin, Sonja, Keller, Ulrich, Balabanov, Stefan, Pabst, Thomas, Vogelhuber, Martin, Hüttmann, Andreas, Wilhelm, Martin, Zijlstra, Josée M, Moccia, Alden, Kuhnert, Georg, Bröckelmann, Paul J, von Tresckow, Bastian, Fuchs, Michael, Klimm, Beate, Rosenwald, Andreas, Eich, Hans, Baues, Christian, Marnitz, Simone, Hallek, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas

Volltext

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Tri... von Bröckelmann, Paul J, Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa V, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Kaul, Helen, Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, Engert, Andreas, von Tresckow, Bastian

Volltext

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial von Bröckelmann, Paul J, Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa V, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Kaul, Helen, Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, Engert, Andreas, von Tresckow, Bastian

Volltext

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial von Bröckelmann, Paul J, Goergen, Helen, Keller, Ulrich, Meissner, Julia, Trautmann, Karolin, Halbsguth, Teresa V, Sasse, Stephanie, Sökler, Martin, Kerkhoff, Andrea, Mathas, Stephan, Hüttmann, Andreas, Bormann, Matthias, Zimmermann, Andreas, Fuchs, Michael, von Tresckow, Bastian, Baues, Christian, Rosenwald, Andreas, Klapper, Wolfram, Kobe, Carsten, Borchmann, Peter, Engert, Andreas

Volltext

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL) von Bröckelmann, Paul J, Goergen, Helen, Keller, Ulrich, Meissner, Julia, Ordemann, Rainer, Halbsguth, Teresa V, Sasse, Stephanie, Sökler, Martin, Kerkhoff, Andrea, Mathas, Stephan, Hüttmann, Andreas, Bormann, Matthias, Zimmermann, Andreas, Fuchs, Michael, von Tresckow, Bastian, Baues, Christian, Rosenwald, Andreas, Klapper, Wolfram, Kobe, Carsten, Borchmann, Peter, Engert, Andreas

Volltext